Uganda & Serum Institute of India

Uganda: Uganda has also reported Ebola cases linked to the outbreak, leading to heightened surveillance and isolation protocols.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate for the Bundibugyo strain of Ebola, positioning itself as a key player in global health security and potentially increasing its market value and reputation.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

Uganda: Uganda has confirmed nine cases of Ebola Bundibugyo, including one death, indicating the regional spread of the outbreak.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.